XLO vs. ALIM, PRQR, CNTX, SGMT, CYBN, RAPT, INCR, YMTX, RZLT, and IMAB
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Alimera Sciences (ALIM), ProQR Therapeutics (PRQR), Context Therapeutics (CNTX), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), InterCure (INCR), Yumanity Therapeutics (YMTX), Rezolute (RZLT), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
Xilio Therapeutics (NASDAQ:XLO) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
Xilio Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Xilio Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -23.74%. Alimera Sciences' return on equity of -53.49% beat Xilio Therapeutics' return on equity.
Alimera Sciences received 345 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 57.70% of users gave Alimera Sciences an outperform vote.
Alimera Sciences has a consensus price target of $8.00, indicating a potential upside of 159.74%. Given Alimera Sciences' higher probable upside, analysts clearly believe Alimera Sciences is more favorable than Xilio Therapeutics.
In the previous week, Alimera Sciences had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Alimera Sciences and 1 mentions for Xilio Therapeutics. Alimera Sciences' average media sentiment score of 1.54 beat Xilio Therapeutics' score of 0.92 indicating that Alimera Sciences is being referred to more favorably in the news media.
Alimera Sciences has higher revenue and earnings than Xilio Therapeutics. Alimera Sciences is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Alimera Sciences beats Xilio Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
